The QualityStocks Daily Tuesday, November 30th, 2021

Today's Top 3 Investment Newsletters

MarketClub Analysis(CPIX) $5.0300 +128.64%

QualityStocks(TOMZ) $1.7300 +49.14%

Pennystockmania(AVRN) $0.0205 +20.59%

The QualityStocks Daily Stock List

NuZee, Inc. (NUZE)

We reported earlier on NuZee, Inc. (NUZE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NuZee, Inc. concentrates on building beverage brands, which offer functional and nutritional benefits. The Company (d/b/a Coffee Blenders®) is the pioneer in functional coffee. It offers gourmet specialty grade coffee in convenient single serve cups using only natural ingredients with clinically supported nutraceuticals. NuZee has its corporate office in Vista, California. Established in 2011, the Company lists on the OTCQB.

NuZee manufactures and sells its Drip Cup line of single serve, pour-over functional coffees. These include Lean Cup® (for weight loss), Think Cup® (for cognitive performance), Relax Cup® (for stress reduction), Active Cup® (for a pre-workout boost of energy), Nude Cup® (100 percent Arabica coffee with no function), and Matcha Cup tea. In addition, NuZee manufactures and sells its Whole Bean coffee line.

NuZee has its ready-to-drink (RTD) gourmet, functional, cold brew coffee line. This product was first available at independent retailers and convenience stores across Southern California. A national roll-out is continuing.

NuZee has undertaken the expansion of its existing production facility in Vista, California. This is to accommodate the growth of its Drip Cup line of functional gourmet coffee sold under the Coffee Blenders® brand name. NuZee adds two new Drip Cup co-packing machines and upgrades process automation as part of the expansion.

NuZee’s customers include B2B (Business-to-Business) multi-store retail chains and wholesale distributors that deliver to chain and independent stores. Also, NuZee sells its products to office and home delivery services that deliver coffee and water to homes and businesses locally.

NuZee earlier announced that it created a new, wholly-owned subsidiary called NuZee KOREA LTD. NuZee KOREA will manage sales, marketing and associated activities for the Coffee Blenders’ line of Drip Cup functional coffees throughout Asia.

NuZee, Inc. (NUZE), closed Tuesday's trading session at $4.65, up 31.3559%, on 32,102,684 volume with 100,020 trades. The average volume for the last 3 months is 31.702M and the stock's 52-week low/high is $1.90/$14.50.

TOMI Environmental Solutions (TOMZ)

QualityStocks, Stockpalooza, Open Water Investments, Nebula Stocks, Wealth Insider Alert, Stock Traders Chat, Stock Exploder, SmallCapVoice, Serious Speculator, Research Driven Investor, Penny stock Profitz, Investor Relations and Barchart reported earlier on TOMI Environmental Solutions (TOMZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TOMI Environmental Solutions Inc. (NASDAQ: TOMZ) is an infectious disease control and bacteria decontamination firm that is engaged in the provision of environmental solutions for indoor surface decontamination.

The firm has its headquarters in Frederick, Maryland and was incorporated in 1979, on September 18th by Halden S. Shane. It serves consumers in the U.S. as well as internationally. The firm operates as part of the other specialty trade contractors’ industry and has four companies in its corporate family.

The enterprise’s products and services include the SteraMist Hospital disinfection cart which is used to disinfect patient rooms and operating rooms, emergency environments, ambulances and pharmacies in a health care facility or hospital; a remotely controlled system dubbed SteraMist Environment system which offers complete room decontamination/disinfection of a sealed space. It also provides a fully portable spray decontamination/disinfection system dubbed SteraMist Surface Unit which offers quick turnover for any affected space. In addition to this, the company also offers iHP corporate service disinfection, the SteraMist custom engineered system and the iHP plasma decontamination chamber. Furthermore, it also manufactures and sells a hydrogen peroxide-based mist dubbed SteraMist Binary Ionization Tech.

The company products and services are used in hospitals, the cannabis market, schools, ambulances, pharmaceutical firms, bio-safety labs, vivariums, office buildings, cruise ships, transportation industry and clean rooms, among others.

The firm recently secured a contract to install a iHP custom engineered system for sterilization in a major pharmaceutical firm in Europe. This project and its successful completion will present a significant opportunity for the firm to develop its relationship with the pharmaceutical company while also extending the firm’s consumer reach, which will boost investments into the firm as well as boost the company’s growth.

TOMI Environmental Solutions (TOMZ), closed Tuesday's trading session at $1.73, up 49.1379%, on 13,124,389 volume with 24,460 trades. The average volume for the last 3 months is 12.079M and the stock's 52-week low/high is $1.07/$6.50.

Cumberland Pharmaceuticals (CPIX)

MarketBeat, Zacks, SmarTrend Newsletters, QualityStocks, CRWEWallStreet, PennyOmega, DrStockPick, TraderPower, Marketbeat.com, CRWEPicks, CRWEFinance, SmallCapVoice, PennyToBuck, BestOtc, StreetInsider, StockHotTips, StockMarketWatch, StockOodles, BUYINS.NET, Barchart, Daily Markets, Market FN, AnotherWinningTrade, Momentum Traders, Stock Research Newsletter, Street Insider, Tiny Gems and MarketClub Analysis reported earlier on Cumberland Pharmaceuticals (CPIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (FRA: CBJ) is a specialty pharmaceutical firm that is engaged in acquiring, developing and commercializing branded prescription products for rheumatology, gastroenterology and hospital acute care in the U.S. to address poorly met or unmet medical needs.

The firm has its headquarters in Nashville, Tennessee and was founded in 1999. It operates in the healthcare sector, under the biotech and pharma sub-industry. Cumberland Pharmaceuticals sells and markets its products through district managers and sales representatives.

The enterprise’s product pipeline is made up of a formulation that was developed for the treatment of duchenne muscular dystrophy, systemic sclerosis and aspirin-exacerbated respiratory disease dubbed ifetroban, which is currently undergoing a phase 2 clinical trial. The formulation recently concluded phase 2 clinical trials evaluating its effectiveness in treating portal hypertension and hepatorenal syndrome. In addition to this, the enterprise is also involved in the development of the RediTrex injection, indicated for disabling psoriasis and treating severe psoriatic and juvenile idiopathic arthritis as well as active rheumatoid arthritis; the Vibative injection indicated for the treatment of various severe bacterial infections and the Vaprisol injection indicated for the treatment of hypervolemic and euvolemic hyponatremia. Furthermore, it also develops Omeclamox-Pak for treating duodenal ulcer disease and Helicobacter pylori infection; a prescription laxative dubbed Kristalose developed to treat acute and chronic constipation; an injection known as Caldolor for treating fever and pain; and an injection termed Acetadote, which is indicated for treating acetaminophen poisoning.

The company’s Vibativ injection has been found to be effective in the treatment of secondary bacterial infections in coronavirus patients, as per patient case studies that were recently released. This formulation, when brought to the market, will cater to a poorly met need and extend the firm’s consumer reach, which will in turn bring in more investors.

Cumberland Pharmaceuticals (CPIX), closed Tuesday's trading session at $5.03, up 128.6364%, on 207,687,987 volume with 717,170 trades. The average volume for the last 3 months is 206.293M and the stock's 52-week low/high is $2.20/$5.4799.

GBS Inc. (GBS)

TradersPro and QualityStocks reported earlier on GBS Inc. (GBS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GBS Inc. (NASDAQ: GBS) (FRA: 12Q0) is a biosensor diagnostics technology firm that is engaged in developing diagnosis platforms for tumors.

The firm has its headquarters in New York, the United States and was incorporated in 2016. Prior to its name change in September 2019, the firm was known as Glucose Biosensor Systems Holdings Inc. It operates in the health care sector, under the biotech and pharma sub-industry. The firm serves consumers in the United States and is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

The company’s objective is to put the power of real-time, non-invasive diagnostic testing in the hands of primary health practitioners and patients at the point of care. It is party to a research agreement with the School of Public Health at Johns Hopkins Bloomberg, which involves developing saliva-based diagnostic tests.

The enterprise’s product pipeline comprises of a saliva glucose monitoring system dubbed Saliva Glucose Biosensor, which has been developed for the management of diabetes. It is also involved in the development of a SARS-CoV-2 antibody biosensor, which is a real-time, non-invasive antibody test that can be used to monitor immunity and infection levels in the fight against the coronavirus. In addition to this, the enterprise is also engaged in the development of other diagnostic tests in the areas of hormones, immunology, tumor markers and biochemistry.

The firm recently reported its financial results for its first quarter of 2021, which highlight the progression of the firm’s programs. It is currently working on bringing its antibody monitoring test to the market after the EUA has given its authorization. This approval will help boost investments into the firm.

GBS Inc. (GBS), closed Tuesday's trading session at $1.98, up 22.2222%, on 32,487,686 volume with 76,090 trades. The average volume for the last 3 months is 32.333M and the stock's 52-week low/high is $1.55/$14.2399.

Whiting USA Trust II (WHZT)

StockOodles, QualityStocks, StocksEarning and MarketBeat reported earlier on Whiting USA Trust II (WHZT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Whiting USA Trust II holds a term net profits interest in the oil and gas producing properties located in the Permian Basin, Rocky Mountains, Gulf Coast, and Mid-Continent regions. Whiting USA Trust II is a subsidiary of Whiting Petroleum Corporation. The Company lists on the OTC Markets. Established in 2011, Whiting USA Trust II has its corporate office in Houston, Texas.

As of December 31, 2018, the Company’s oil and gas properties included interests in roughly 367.8 net producing oil and natural gas wells. These are situated in 46 predominately mature fields with established production profiles in 10 States.

The Trust’s net profits interest (NPI), the only asset of the Trust other than cash reserves held for future Trust expenses, represents the right to receive 90 percent of the net proceeds from Whiting Petroleum Corporation’s interests in certain existing oil and natural gas properties located mainly in the aforementioned Rocky Mountains, Permian Basin, Gulf Coast and Mid-Continent regions of the U.S.

The Company’s parent, Whiting Petroleum Corporation, is an independent oil and gas company. It develops, produces, acquires and explores for crude oil, natural gas and natural gas liquids mainly in the Rocky Mountains region of the U.S. The Company’s largest projects are in the Bakken and Three Forks plays in North Dakota and Montana and the Niobrara play in northeast Colorado.

Whiting USA Trust II (WHZT), closed Tuesday's trading session at $0.31, off by 20.5128%, on 526,140 volume with 195 trades. The average volume for the last 3 months is 526,140 and the stock's 52-week low/high is $0.0001/$0.64.

Gritstone Oncology, Inc. (GRTS)

StreetInsider, MarketClub Analysis, MarketBeat, BUYINS.NET, TradersPro, StockMarketWatch and QualityStocks reported earlier on Gritstone Oncology, Inc. (GRTS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gritstone Oncology, Inc. is a clinical-stage biotechnology company listed on the NasdaqGS. It is developing the next generation of cancer immunotherapies to fight multiple cancer types. The Company’s approach centers on the individual nature of a patient’s tumor. The Company’s approach seeks to produce a therapeutic immune response in these patients through unleashing the natural power of a patient’s immune system to recognize tumor antigens in order to destroy cancer cells. Established in 2015, Gritstone Oncology has its corporate office in Emeryville, California.

The Company develops its products through taking advantage of two key pillars. One is a proprietary machine learning-based platform, Gritstone EDGE™, designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient’s tumor cells. The second is the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to potentially drive the patient’s immune system to specifically attack and destroy tumors.

Gritstone Oncology’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are undergoing evaluation in clinical studies. In addition, novel tumor-specific antigens can provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors. The Company’s BiSAb program is now in lead optimization.

Gritstone Oncology recently announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by mutations found within the Omicron (B.1.1.529) variant, reinforcing the platform’s potential to address emerging variants of concern.

Gritstone’s CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering a stabilized Spike protein and highly conserved TCEs derived from other SARS-CoV-2 viral genes, offering the potential for more durable protection and broader immunity against SARS-CoV-2 variants. Delivery vectors can comprise self-amplifying mRNA (SAM), a chimpanzee adenovirus (ChAd), or both (mix-and-match).

Gritstone Oncology, Inc. (GRTS), closed Tuesday's trading session at $13.2, up 25.7143%, on 9,532,419 volume with 45,380 trades. The average volume for the last 3 months is 7.662M and the stock's 52-week low/high is $2.86/$35.20.

MEI Pharma, Inc. (MEIP)

InvestorPlace, MarketBeat, The Street, StockMarketWatch, Schaeffer's, PennyStocks24, BUYINS.NET, StreetInsider, SmarTrend Newsletters, Wall Street Resources, Pennybuster, Daily Trade Alert, Hit and Run Candle Sticks, OTCPicks, TradersPro, TraderPower, Trades Of The Day, QualityStocks, UltimatePennyStock, Streetwise Reports, Rick Saddler, MarketClub Analysis, WiseAlerts, Jason Bond, Wallstreetlivechat, Street Insider and Penny Stock Prodigy reported earlier on MEI Pharma, Inc. (MEIP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MEI Pharma, Inc. is a late-stage pharmaceutical company focused on advancing new therapies for cancer. Its portfolio of drug candidates contains four clinical-stage assets. These include one candidate in an ongoing worldwide registration trial and another candidate in a Phase 2 clinical trial that may support an accelerated approval marketing application with the U.S. Food and Drug Administration (FDA).

Established in 2000, MEI Pharma has its head office in San Diego, California. The Company previously went by the name Marshall Edwards, Inc. It changed its name to MEI Pharma, Inc. in July of 2012. MEI Pharma’s shares trade on the NasdaqGS.

Each of the Company’s pipeline candidates takes advantage of a different mechanism of action with the aim of developing therapeutic options that are differentiated, address unmet medical needs, and deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. MEI Pharma’s drug candidates target different mechanisms vital to overcoming cancer progression and drug resistance. These are Pracinostat, an oral HDAC inhibitor; ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.

Helsinn Group, a Swiss pharmaceutical group centered on building quality cancer care and rare disease products, and MEI Pharma previously announced new data from the Phase 2 study evaluating pracinostat, an oral pan-histone deacetylase inhibitor (HDACi), in combination with azacitidine in patients with high and very-high risk myelodysplastic syndromes previously untreated with hypomethylating agents. The new data from the Phase 2 study (n=64) demonstrated an estimated median overall survival (OS) rate of 23.5 months with a 1-year OS rate of 77 percent. The median follow-up was 17.6 months (range, 15.7–18.8) and the overall response rate (ORR) was 33 percent (21/64); all are complete responses (CR).

Additionally, MEI Pharma and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) announced that updated Phase 1b data on ME-401, its investigational oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor drug-candidate in clinical development for the treatment of follicular lymphoma and other B-cell malignancies, will be presented in a poster session at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress to take place June 11 to June 14, 2020.

Kyowa Kirin is an international specialty pharmaceutical company creating unique medical solutions using the latest biotechnology. It focuses on creating new value in four therapeutic areas: nephrology, oncology, immunology/allergy, as well as neurology.

The companies recently touted pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC) assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete response.

The ongoing TIDAL study (NCT03768505) is a global, open-label Phase 2 trial evaluating zandelisib as a single agent across two disease cohorts: the first cohort for the treatment of adults with r/r FL and the second cohort for r/r marginal zone lymphoma (MZL), in both cases after failure of at least two prior systemic therapies, including chemotherapy and an anti-CD20 antibody. Enrollment in the FL cohort is complete; enrollment in the MZL cohort is ongoing. Subject to the results and discussion with the U.S. Food and Drug Administration (FDA), TIDAL study data from each study cohort are intended to be submitted to the FDA to support accelerated approval marketing applications.

MEI Pharma, Inc. (MEIP), closed Tuesday's trading session at $3.37, up 37.551%, on 26,879,960 volume with 84,740 trades. The average volume for the last 3 months is 26.725M and the stock's 52-week low/high is $2.40/$4.575.

Palatin Technologies (PTN)

MarketBeat, StreetInsider, BUYINS.NET, StockMarketWatch, The Sandman, Greenbackers, QualityStocks, The Street, StockEgg, Zacks, Kiplinger Today, HotOTC, PennyTrader Publisher, Jason Bond, Otc stock alert, CoolPennyStocks, TopPennyStockMovers, BullRally, Penny Invest, MadPennyStocks, DrStockPick, PennyStockVille, CRWEWallStreet, CRWEFinance, BestOtc, FeedBlitz, Marketbeat.com, Mega Penny Stock Pick, Barchart, PennyOmega, PennyToBuck, Stock Fortune Teller, Stock Rich, Stock Stars, StockHotTips, Stockpalooza, StockRich, Tiny Gems, Trading Concepts, WealthMakers and PennyInvest reported earlier on Palatin Technologies (PTN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Palatin Technologies Inc. (NYSE American: PTN) (FRA: PTNA) is focused on the development of receptor-specific therapeutics for treating different ailments.

The firm has its headquarters in Cranbury, New Jersey and was incorporated in 1986, on November 21st by John K.A. Prendergast and Carl Spana. The firm serves consumers in the United States.

The biopharmaceutical company develops medicines based off of molecules which modulate activity of the natriuretic and melanocortin peptide receptor systems. The latter receptor system has effects on immune system responses, inflammation, sexual function, metabolism and food intake. On the other hand, the former receptor system regulates tissue homeostasis and cardiovascular functions.

The enterprise’s product candidates are targeted, receptor-specific peptide therapeutics for treating illnesses with unmet medical needs which have commercial potential. They include an oral selective melanocortin receptor (MCr) agonist peptide dubbed PL8177, which has concluded a phase 1 trial evaluating its effectiveness in treating inflammatory bowel diseases, and a MCr agonist known as Vyleesi, for treating premenopausal women with hypoactive sexual desire disorder. It also develops a peptide melanocortin agonist active at different MCrs dubbed PL9643, for anti-inflammatory ocular indications. In addition to this, the enterprise develops melanocortin peptides indicated for diabetic retinopathy treatment; a natriuretic peptide receptor-A (NPR)-A and NPR-binder for the treatment of fibrotic and cardiovascular ailments known as PL5028; and aNPR-A agonist dubbed PL3994, for cardiovascular indications.

The firm recently released its latest financial results of 2021 which show increases in revenues. It is currently focused the advancement of its melanocortin agonist programs.

Palatin Technologies (PTN), closed Tuesday's trading session at $0.7149, off by 16.386%, on 51,520,121 volume with 51,740 trades. The average volume for the last 3 months is 50.657M and the stock's 52-week low/high is $0.33/$1.30.

Emmaus Life Sciences (EMMA)

QualityStocks, MarketBeat and RedChip reported earlier on Emmaus Life Sciences (EMMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Emmaus Life Sciences Inc. (OTCQX: EMMA) is a biopharmaceutical firm that is focused on discovering, developing, marketing and commercializing therapies and treatments for orphan and rare diseases.

The firm has its headquarters in Torrance, California and was incorporated in 1987, on March 20th. Prior to its name change in September 2011, the firm was known as Emmaus Holdings Inc. The firm serves consumers around the globe, with a focus on the United States.

The company is party to a collaboration agreement with Kainos Medicine Inc., which entails the development of Kainos Medicine’s patented KM10544 formulation as a drug for cancer. It is also focused on developing treatments for genetic disorders.

The enterprise’s products include an oral pharmaceutical grade L-glutamine treatment dubbed Endari, which has been developed to treat sickle cell disease in pediatric patients aged 5 and above as well as in adults. The treatment has received Orphan Medicinal designation and Orphan Drug designation from the European Commission and the Food and Drug Administration respectively. Endari was well tolerated in adult and pediatric patients alike, with experts noting that it offers an effective and safe means to reduce the frequency of sickle cell crises in patients suffering from sickle cell disease. Other products in the enterprise’s pipeline include diverticulosis and cell sheet engineering.

The firm recently entered into a partnership agreement with UpScript, which involves the provision of telehealth solutions to patients with sickle cell disease, which will expand access to its Endari product. This move will be good for the firm’s growth as well as investments into the firm.

Emmaus Life Sciences (EMMA), closed Tuesday's trading session at $2.15, up 43.3333%, on 313,843 volume with 333 trades. The average volume for the last 3 months is 313,843 and the stock's 52-week low/high is $0.9125/$4.00.

Flower One Holdings (FLOOF)

QualityStocks, CFN Media Group, MarketBeat and InvestorPlace reported earlier on Flower One Holdings (FLOOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings Inc. (OTCQX: FLOOF) (FRA: F11) is a holding firm that is focused on the cultivation and production of recreational and medical marijuana and marijuana products.

The firm has its headquarters in Toronto, Canada and was incorporated in 2007, on January 9th. The firm serves consumers in Canada and the United States.

The company combines over two decades of greenhouse operational excellence with best-in-class marijuana operators to provide scalable, reliable and consistent fulfillment to an increasing number of industry-leading marijuana brands. It operates through its subsidiaries, which include North Las Vegas Services Inc., CN Landco LLC, CN Landco II LLC, Cana Nevada Crop, FO Labor Management Ltd and Flower One Corp.

The enterprise is focused on investing toward the development of about 400,000 ft2 greenhouse space in Nevada, which has been dedicated to growing and producing its raw materials. It also has a 55,000 ft2 marijuana production facility, which is involved in the processing, manufacturing and packaging of its products. The enterprise’s products include full spectrum oils, flower and distillates, to finished consumer packaged goods, which comprise of a variety of topicals, edibles, concentrates and prerolls. In addition to this, it leases a warehouse in North Las Vegas. The enterprise sells its products to dispensaries directly, and also engages in contract growing, production and packaging consumer marijuana brands.

The firm’s CEO was recently appointed to the U.S. Cannabis Council’s Board of Directors. This move will allow the firm to join other marijuana industry leaders and position it well to advocate for meaningful reform, which may have a positive influence on its growth and investments.

Flower One Holdings (FLOOF), closed Tuesday's trading session at $0.051, off by 31.9092%, on 4,395,026 volume with 220 trades. The average volume for the last 3 months is 4.395M and the stock's 52-week low/high is $0.0504/$0.3728.

Generex Biotechnology (GNBT)

Greenbackers, QualityStocks, OTC Advisors, ShamrockStocks, SmallCapVoice, OTCPicks, Stock Market News Alert, TopPennyStockMovers, CoolPennyStocks, HotOTC, MarketBeat, StockEgg, Stock Rich, MicrocapVoice, Penny Invest, Standout Stocks, Penny Performers, BullRally, Stock Stars, PennyTrader Publisher, The Street, Stockpalooza, FeedBlitz, PoliticsAndMyPortfolio, Mr. Liquid, DrStockPick, AllPennyStocks, Global Equity Report, CRWEPicks, CRWEFinance, BreakthroughStocks Team, BloomMoney, BestPicksEver, Beacon Equity Research, Bull Warrior Stocks, Wall Street Grand, Investor Ideas, M2 Communications, Monster Stock Alerts, StockHideout, 24-7 Stock Alert, Zacks, PennyInvest, PennyOmega, PennyTrader, The Dean, SteroidStocks, Stock Beast, Stock Preacher and Momentum Traders reported earlier on Generex Biotechnology (GNBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Generex Biotechnology Corporation (OTCQB: GNBT) is an integrated healthcare holding firm that is focused on the development and commercialization of drug delivery systems and technologies.

The firm has its headquarters in Miramar, Florida and was incorporated in 1997, on September 4th by Rose C. Perri. The firm serves consumers around the globe, with a focus on Canada, the United States, Italy and England.

The company operates through one segment, namely, the research and development of drug delivery systems and technologies for immunological and metabolic ailments. It is primarily engaged in the administration of formulations of large molecule therapies to the oral cavity of an individual, through the use of a hand-held aerosol applicator.

The enterprise’s product pipeline comprises of a synthetic peptide vaccine dubbed AE37, which stimulates an immune response against tumors expressing the HER-2/neuroncogene, and has concluded phase 2 clinical trials on its use in the treatment of prostate cancer and breast cancer; and an oral insulin product known as Generex Oral-lyn. It also develops and manufactures a wound conforming gel dubbed Excellagen; as well as in-vitro medical diagnostics for infectious ailments, including syphilis, hepatitis B and C, malaria, TB and HIV. This is in addition to manufacturing and selling ankle and foot surgical kits, which include screws and plates; and distributing regenerative medicine products, medical devices, biologics, artificial joints, orthopedic implants and other surgical supplies.

The company’s Olaregen Therapeutix subsidiary recently entered into a distribution agreement with Nexgen Medical Inc., which will help the company expand while also extending its consumer reach into countries in Southeast Asia, including the Philippines, Vietnam, Indonesia, Thailand and Singapore.

Generex Biotechnology (GNBT), closed Tuesday's trading session at $0.1195, up 15.7385%, on 263,593 volume with 48 trades. The average volume for the last 3 months is 258,593 and the stock's 52-week low/high is $0.0673/$0.75.

Ocuphire Pharma (OCUP)

TradersPro, MarketBeat, StockOnion, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter, MarketClub Analysis and Buzz Stocks reported earlier on Ocuphire Pharma (OCUP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Ocuphire Pharma Inc. (NASDAQ: OCUP) (FRA: R3X1) is a clinical stage ophthalmic biopharmaceutical firm that is engaged in the development and commercialization of therapies for treating various eye disorders.

The firm has its headquarters in Farmington Hills, Michigan and was incorporated in February 2018 by Alan R. Meyer and Mina Patel Soouch. Prior to its name change, the firm was known as Rexahn Pharmaceuticals Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The enterprise’s product pipeline comprises of a once-daily preservative-free eye drop formulation dubbed Nyxol eye drops, which is undergoing phase 3 clinical trials for pharmacologically induced mydriasis, night vision disturbances and dim light. The phentolaminemesylate formulation, which has been designed to improve visual acuity and decrease pupil diameter, is also undergoing a phase 2 clinical trial evaluating its effectiveness in treating presbyopia. It also develops a two-times-a-day oral tablet known as APX3330, which has been designed to inhibit inflammation and angiogenesis pathways relevant to choroidal and retinal vascular ailments, like diabetic macular edema and diabetic retinopathy. In addition to this, the enterprise is involved in the development of APX2014 and APX2009, which are 2nd generation pre-clinical product candidates and analogs of APX3330.

The company is focused on building significant value for itself and its shareholders, as well as exploring opportunities to acquire additional ophthalmic assets. This is in addition to seeking strategic partners in key global markets that align with its growth strategy.

Ocuphire Pharma (OCUP), closed Tuesday's trading session at $3.91, off by 6.235%, on 2,326,509 volume with 10,120 trades. The average volume for the last 3 months is 2.305M and the stock's 52-week low/high is $3.35/$13.812.

The QualityStocks Company Corner

Tingo Inc. (OTCQB: IWBB)

The QualityStocks Daily Newsletter would like to spotlight Tingo Inc. (IWBB).

Tingo (OTCQB: IWBB) recently applied to list its shares for trading with the New York Stock Exchange (“NYSE”), forming part of efforts to broaden its appeal to U.S. and international investors. Although there are no guarantees that its listing application will be accepted, the company has reiterated its belief that it will satisfy the NYSE’s initial listing criteria. A recent article quotes Tingo CEO Dozy Mmobuosi as saying: “The NYSE is the main stock exchange in the United States and one that will raise our profile to the broader investment community. The bottom-up list will increase liquidity in our stocks and ultimately create shareholder value in line with our international peer groups.” A company whose business model is based around four core pillars — device as a service, mobile voice and data services, the Nwassa Marketplace Platform, and Tingo Pay — Tingo aims to be Africa’s leading agri-fintech company, focused on driving financial inclusion, social betterment and wealth creation within Africa’s agricultural sectors. “Tingo Inc. ranks amongst the rarest of companies — driving social change whilst simultaneously boosting shareholder returns.” To view the full article, visit https://ccw.fm/gjqHz

Tingo Inc. (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities.

Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries.

Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo.

Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products.

Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology.

The African Continental Free Trade (ACFT) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up.

Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria.

Businesses

Tingo has four core businesses:

  • Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
  • Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
  • Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
  • TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

  • Tingo Wallet top-up
  • Peer to Peer payments, inclusive of merchant payments at the stores
  • Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
  • Pension payments
  • QR code payment services

Market Opportunity

Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology.

Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture.

Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness.

Management Team

Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia.

Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant.

Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues.

Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world.

Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (FDI) in the financial services sector and facilitate greater public/private cooperation.

Tingo Inc. (OTCQB: IWBB), closed Tuesday's trading session at $3.95, up 5.8981%, on 100 volume with 1 trade. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $1.01/$8.98.

Recent News

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF)

The QualityStocks Daily Newsletter would like to spotlight Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF).

  • MINDCURE plans to schedule a pre-IND meeting with the FDA for its Desire Project during Q1 2022 with a subsequent Phase 2 trial to begin Q3 2022
  • The company expects that the GLP supply of ibogaine will be available for distribution to research partners in Q2 2022
  • Information on MC-106 and MC-808, an expansion of MINDCURE’s drug pipeline, will be released during Q2 2022

As a member of the Digital Therapeutics Alliance, Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) delivers digital therapeutics (“DTx”) that are evidence-based interventions driven by high-quality software to prevent, manage, and treat medical disorders or diseases. DTx can be used independently or with other medications, devices, or therapies, to optimize outcomes and patient care. MINDCURE is a leader in advanced proprietary technology and research centered around psychedelics and is currently advancing multiple programs and products to this end. A survey conducted by Deloitte has found that many young individuals are experiencing high levels of stress. Of the total population surveyed, about 45% of Gen Z respondents and 40% of Millennials admitted to being stressed most or all of the time. The survey also highlights that high numbers in each group admitted that their financial future was a substantial source of this stress. Financial stress is not a new thing. However, the increasing generational wealth gap complicates things. For example, the cost of purchasing a house today is much higher than the cost when people in our grandparents’ generation were purchasing houses, and this is after increasing salaries and inflation have been adjusted for. Whether due to money issues or other factors, the escalation of cases of mental health disorders around the world has given impetus to plenty of companies such as Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) to search for novel treatments that can offer superior clinical outcomes to the patients who aren’t benefiting from the existing remedies.

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.

MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.

MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.

Technology

Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.

iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (MVP) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.

Research

In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.

The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.

Market Outlook

MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.

The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.

Management Team

Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.

Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.

Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.

Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.

Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.

Mind Cure Health Inc. (OTCQX: MCURF), closed Tuesday's trading session at $0.205, up 2.9116%, on 83,083 volume with 35 trades. The average volume for the last 3 months is 83,083 and the stock's 52-week low/high is $0.1954/$0.8584.

Recent News

StorEn Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight StorEn Technologies Inc.

StorEn Technologies Inc. delivers proprietary vanadium flow batteries aimed at revolutionizing the world of residential and industrial energy storage. With an expected life of 25 years and more than 15,000 cycles, the company’s batteries satisfy market demand for efficient, durable and cost-effective energy storage, enabling self-consumption of self-produced electricity and the transition toward a carbon-free economy.

The company is currently accepting investments through a Reg A+ offering on StartEngine. For more information, view the company’s Offering Circular. To date, StorEn has raised more than $6.7 million from over 5,000 investors on the crowdfunding platform, along with venture capital from the ANYSEED Fund.

StorEn’s growing intellectual property portfolio currently features four international PCT patents and five trademarks, securing its innovative IP in all major regions and countries in the world.

A Disruptive Approach to Energy Storage

StorEn’s patent-pending all-vanadium flow battery technology offers a variety of benefits over existing lithium and lead acid batteries, including:

  • Eco-Friendly: StorEn vanadium flow batteries are 100% recyclable, featuring a 100% reusable electrolyte and low GHGs emissions.
  • Safe: The company’s batteries are both non-flammable and non-explosive.
  • Cost Effective: StorEn’s cost/kWh is comparable to that of lithium batteries, but its cost/cycle is up to four times lower than lithium batteries, thanks to the exceptional duration of over 25 years or 15,000 cycles.
  • Efficient: The company’s vanadium flow battery technology offers the highest power density thanks to MULTIGRIDS™, +35% in energy storage capacity with the same volume and +5% round-trip efficiency in harsh climate thanks to its proprietary THERMASTABLE™ geothermal design. StorEn’s solution is also virtually maintenance-free, leveraging its proprietary RESAFE™ and EQUILEVELS™ technologies.

StorEn batteries are modular and configurable in either 20kWh or 30kWh versions sharing the same Power Module, ensuring that customers only pay for the energy capacity they really need. The ability to connect additional modules allows for maximum flexibility.

Traction in the Market

To date, the total investment in the company’s technology has exceeded $2 million, and it is already putting these efforts to work. StorEn secured a $500,000 order in Australia to provide 30 kWh StorEn vanadium flow batteries to a renewable hydrogen plant at Queensland University of Technology (QUT), where researchers will develop safety standards for the future use of vanadium flow batteries. The first battery – the first of its kind in Australia – was installed in Brisbane in November 2020 at the National Battery Testing Centre (NBTC), a flagship project of the Future Battery Industries CRC. Additional units are being manufactured.

StorEn has also entered into a supply chain deal with Multicom Resources, an Australian mining company which is the owner of two vanadium mines. Through this agreement, StorEn has secured the exclusive availability of vanadium for up to 20 years with either a price cap or at market price, whichever is lower.

Capitalizing on the Australian government’s support to fulfil the country’s energy storage opportunity, Multicom’s subsidiary, Freedom Energy, has agreed to assemble StorEn batteries within Australia and distribute them widely across the wider Asia Pacific region. In addition to an initial pilot plant, Multicom has completed a concept design for a full-scale manufacturing facility for StorEn batteries.

Market Opportunity

The shift to renewable energy sources is on, with governments around the globe discussing and implementing initiatives to reduce dependence on fossil fuels. McKinsey & Company research suggests that, by 2035, more than 50% of global power generation will come from renewable sources.

Spurred on by this transition, demand for reliable energy storage systems is expected to attain exponential growth in the coming years, positively influencing the energy storage industry landscape, according to Grand View Research.

Data from Fortune Business Insights projects that the global battery energy storage market will reach $19.74 billion by 2027, recording a CAGR of 20.4% from 2020 to 2027. The research firm suggests that improving access to electricity across the globe will be a prominent trend shaping the growth trajectory of this market, which is particularly noteworthy for StorEn and its TITANstack™ grid-scale energy storage solution.

Over a billion people still do not have access to electricity. The electrification of these unserved communities can become a reality with mini grids, using solar plus energy storage. StorEn’s vanadium flow batteries could be a key technology toward providing universal access to affordable, longer lasting and dependable energy. In support this critical mission, StorEn Technologies is a member of the Alliance for Rural Electrification and the Global Off-Grid Lighting Association.

Management Team

StorEn is led by an executive team with decades of experience in the vanadium flow battery industry.

Founder Carlo Brovero has served as the company’s chief executive officer, treasurer and director since its inception in January 2017. From 2013 to 2019, Mr. Brovero served as a consultant for eCaral Ltd., a management consulting firm. From 2013 to 2015, he served as an advisory board member for Proxhima S.r.l., a vanadium flow battery company, which was sold to the Gala Group, a utility listed on the Milan Stock Exchange. From 2010 to 2016, Mr. Brovero served as International Sales and Marketing Director for iVis Technologies, the manufacturer of an excimer laser therapeutic and refractive platform for corneal surgery. He holds an MBA from Aston University in Birmingham, UK.

Founder Angelo D’Anzi has served as StorEn’s chief technology officer and director since the company’s inception. He is primarily responsible for the technical development of StorEn’s products. Since May 2018, Mr. D’Anzi has also served as a director of Arco Fuel Cells S.r.l., where he is responsible for the company’s fuel cell technical development activities. Mr. D’Anzi co-founded vanadium flow battery company Proxhima in 2013. In 2000, he founded ROEN-EST, a fuel cell company that was eventually acquired by the Morphic Group, a cleantech holding company listed on the Stockholm Stock Exchange. Mr. D’Anzi holds 14 international patents and received the 2003 Sapio Award in the Energy and Transportation category. He holds an MBA from the LUISS Business School in Rome.

Founder Gabriele Colombo has served as secretary of StorEn since its inception. Since 2012, he has also served in various roles ranging from regional manager to CEO with Leonardo Hispania S.A., a subsidiary of the Leonardo Group of Italy, an aerospace, defense and security conglomerate. Mr. Colombo co-founded vanadium flow battery company Proxhima in 2013. He holds an honors degree in computer engineering from the University of Pisa and a master’s degree in business leadership from the University of Genova.


Recent News

chart

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

  • Growth in the uranium mining market is attributable to increase in nuclear fuel spend, reports the Business Research Company
  • Report also noted key factors in projected growth of space, which should reach $10.18 billion by 2020
  • UUUU is the leading U.S. producer of uranium, the fuel for carbon- and emission-free nuclear energy, in the country

The uranium mining market is projected to reach nearly $10.18 billion next year, according to a Business Research Company report, which noted that the industry should see CAGR of 4.6% during the forecast period (https://ibn.fm/vvT93). Energy Fuels (NYSE American: UUUU) (TSX: EFR), the largest producer of uranium in the United States, is committed to playing a significant role in the growing market.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Tuesday's trading session at $8.71, off by 6.2433%, on 4,200,525 volume with 27,440 trades. The average volume for the last 3 months is 4.173M and the stock's 52-week low/high is $1.9321/$11.39.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, owns and partners with multiple synergistic businesses working to create clean and scalable energy solutions. Led by an executive team with extensive EV, OEM and high-growth startup experience, Mullen has evolved over the past decade in sync with technology trends and consumers. The company is working diligently to provide innovative EV options built entirely in the U.S. Its Mullen FIVE EV Crossover, which debuted at the Los Angeles International Auto Show (“LAIAS”) in November 2021, is built on an EV crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different(TM). It is capable of 0-60 in 3.2 seconds with a max speed of 155 mph and an estimated range of 325 miles. “Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high-performance sports car, the DragonFLY,” explains a recent article. In November 2021, Mullen also announced plans to expand its facility in Robinsonville, Mississippi, to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover. “On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.” To view the full article, visit https://ibn.fm/OMIf0

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $7.92, off by 1.4925%, on 519,552 volume with 3,284 trades. The average volume for the last 3 months is 519,552 and the stock's 52-week low/high is $6.95/$19.15.

Recent News

Lottery.com Inc. (NASDAQ: LTRY)

The QualityStocks Daily Newsletter would like to spotlight Lottery.com Inc. (LTRY).

Lottery.com (NASDAQ: LTRY, LTRYW), a leading technology company that is transforming how, where and when the lottery is played, will be participating in the upcoming Jefferies Sports Betting and iGaming Summit. The summit, scheduled to take place on Dec. 2, 2021, will include a fireside chat, which will include Lottery.com cofounder and CEO Tony DiMatteo. The chat will begin at 4 p.m. ET. In addition, DiMatteo will be available to meet with conference attendees. An archived replay of DiMatteo’s presentation will be available for 30 days. Lottery.com is dedicated offering mobile and online platforms that support players and commercial globally to purchase legally sanctioned lottery games. To view the presentation, visit https://ibn.fm/WbQTQ. To view the full press release, visit https://ibn.fm/CKL86.

Lottery.com Inc. (NASDAQ: LTRY) is a next generation platform where consumers can play the lottery online – in browser or via smartphone app. The platform offers users access to official lottery games sanctioned by their individual states and also provides lottery data to more than 400 digital publishers, including Google and Amazon Alexa.

Lottery.com was founded in 2015, launching at the LAUNCH festival and soon turning into a leader in the industry. With headquarters in Austin, Texas, the company is dedicated to helping advance the lottery industry into the digital age and works closely with state regulatory bodies to achieve this goal.

The company recently entered into a definitive agreement for a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC) (“Trident”), which will result in Lottery.com becoming a publicly listed company. Once the transaction is complete, the combined company will be trademarked as Lottery.com, with its common stock to remain listed on Nasdaq under ticker symbol ‘LTRY’.

Lottery.com Online Platform

The Lottery.com online platform works closely with state regulators, advancing the lottery into the digital age. With the online platform, the company offers enhanced regulatory capabilities by leveraging innovative blockchain technology and capturing the untapped market of digitally native players.

Players go online in a browser or through a mobile application to use the interface. The process includes:

  • Players Choose a Game: Players can play officially state sanctioned multi-state games and other games offered in the states in which they live. Players can also find winning numbers, jackpot totals, draw dates and more for hundreds of other lottery games around the world.
  • Players Pick Numbers: Players can play their lucky numbers or do a quick pick of randomized numbers in as simple as two taps. “Tap, Tap, Ticket!”
  • A Safe and Secure Way to Play: Purchases for up to 50 tickets can be made at one time through the online interface. Lottery.com handles everything after purchase, letting users know when they win.
  • Collect All Winnings: Consumers keep 100% of their winnings. All winnings stay in the Lottery.com balance for future ticket purchases, or a cashout can be requested. Company representatives contact winners who hit big jackpots, instructing them on the redemption process.

A Better Way to Play the Lottery

Lottery.com has an innovative e-commerce platform that is using blockchain to maintain an accurate ledger. From 2016 to 2020, Lottery.com grew gross revenue at a CAGR of 363%, and it forecasts gross revenue equal to approximately $71 million in 2021, $279 million in 2022, and $571 million in 2023.

Lottery.com is leveraging a successful playbook, with $398 billion in global lottery sales but only 6.7% online penetration. The large market opportunity is expected to shift to online transactions within the next decade.

The platform is currently available in 12 states across the United States, and the company plans to expand to 34 by the end of 2023. Global expansion is also on the horizon, with partnership plans in Turkey and Ukraine.

Key features that make the Lottery.com experience unique include:

  • All the Games Users Love – For consumers who live in applicable LIVE states, Powerball and Mega Millions are available right from the mobile application.
  • Convenience – Lottery.com makes playing the lottery on mobile devices easy. After setting up an account, users can begin playing in moments or set reminders to play when the jackpot is high.
  • Easy Cashouts – Users can cash out winnings straight to a bank account, safely and securely, with no commissions.

The company is also gamifying charitable giving, fundamentally changing how nonprofits engage with donors and raise funds. WinTogether.org is a platform designed to offer charitable donation sweepstakes to incentivize donors to take action by offering large cash prizes and once-in-a-lifetime experiences.

Strong Advisory Board Presence

Lottery.com is expected to continue to gain support, leaning on the experience of its advisory board and notable investors from the venture capital, gaming and entertainment industries. These include:

  • Jason Robins, CEO of DraftKings Inc. (NASDAQ: DKNG)
  • Ben Narasin, Venture Partner of NEA
  • Peter Diamandis, Chairman of XPRIZE Foundation
  • Matthew Le Merle, Co-Founder and Managing Partner of Fifth Era and Keiretsu Capital
  • Paraag Marathe, President of Enterprises and EVP of Football Operations for the San Francisco 49ers
  • Jamie Gold, The Poker Philanthropist

Management Team

Tony DiMatteo is the Co-Founder and Chief Executive Officer of Lottery.com. He is a serial entrepreneur and highly sought-after industry speaker and thought leader. He has been featured in The Wall Street Journal, Forbes, VentureBeat, TechCrunch Inc. and more for his approach to entrepreneurship, the gaming industry and cryptocurrency.

Matt Clemenson is the Co-Founder and Chief Commercial Officer of Lottery.com. He is responsible for the company’s strategy. Mr. Clemenson was steeped in corporate and enterprise engineering processes at Hotwire and Expedia before going on to be CEO at LesConcierges, the world’s largest concierge company, which merged into John Paul and sold to Accor Hotels. Clemenson and DiMatteo have been partners for more than 10 years.

Ryan Dickinson is the company’s President and Chief Operating Officer. He has a diverse background in business, technology, product, design and sales, which has aided him in producing many successful outcomes throughout his career. Notably, as Senior Vice President of a SaaS company, Mr. Dickinson produced profitability from a negative $1.4 million division within the first year by reinventing the product offerings, streamlining processes and establishing a go-to-market strategy. Additionally, he produced three record breaking revenue years in a row for AccuWeather, the world’s largest weather provider, by increasing every KPI for all flagship properties by no less than 5%.

Luc Vanhal is the company’s Chief Financial Officer. He has served in C-level executive roles since the 1990s, including a nine-year tenure for The Walt Disney Company (NYSE: DIS) from 1990 to 1999. From 2001 to 2004, he managed the development of the World of Warcraft massively multiplayer game, which, by the end of 2020, still had over five million active subscribers. As the CFO of Lottery.com, Mr. Vanhal leads the company’s global finance organization, with treasury responsibility, accounting, analysis and financial planning.

Lottery.com Inc. (LTRY), closed Tuesday's trading session at $6.66, off by 2.2026%, on 648,841 volume with 4,325 trades. The average volume for the last 3 months is 648,841 and the stock's 52-week low/high is $6.22/$17.50.

Recent News

Nemaura Medical Inc. (NASDAQ: NMRD)

The QualityStocks Daily Newsletter would like to spotlight Nemaura Medical Inc. (NASDAQ: NMRD).

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Faz Chowdhury, Ph.D., will present at the Benzinga Global Small Cap Conference. The event is scheduled to be held virtually from Dec. 8-9, 2021. Dr. Chowdhury will deliver his corporate presentation at 3:00 p.m. ET on Dec. 8 and will be available for one-on-one meetings throughout the conference. Interested parties should visit https://ibn.fm/puHmj to register for the event. To view the full press release, visit https://ibn.fm/FRxhP

Nemaura Medical Inc. (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT®, is a wearable, non-invasive and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemaura’s skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Technologies

Digital Solutions for Weight Loss and Potential Reversal of Type 2 Diabetes

This is a digital program that comes with more than a decade of clinical evidence demonstrating excellent efficacy. The company has combined this with its glucose-monitoring platform to bring a product to market to help people with diabetes manage their condition and potentially reverse Type 2 diabetes.

Glucose Monitoring Solutions for Diabetes Prevention and Reversal

Over 420 million people worldwide are living with diabetes, and prediabetes cases total almost three times that number. Undoubtedly, diabetes is an urgent global health crisis. Combining clinical research with patient-friendly technology, Nemaura’s sugarBEAT product delivers a non-invasive, affordable and flexible method of blood glucose tracking for improved diabetes management.

Continuous Lactate Monitoring for Athletic Performance (Non-Medical)

Lactic acid is a key performance indicator for the body and a guide to how well muscles react to long term exertion and recovery. Well-trained athletes and those who regularly engage in sports are very efficient at faster lactate ‘recycling’ for extra energy (ATP). Nemaura expects to launch its lactate sensor to the sports and personal training market in 2022.

Continuous Lactate Monitoring in Disease State (Medical)

An increase in blood lactate levels is also a marker of critical disease states. Recent publications have indicated the presence of elevated lactate levels in patients with COVID-19 infection. Nemaura has developed a lactate sensor that is being integrated into the company’s platform, which will be submitted for regulatory clearance upon completion of requisite clinical studies.

Continuous Temperature Monitoring for Viral Infection Detection and Disease Progression

A person’s body temperature says a lot about their health. Several diseases, including COVID-19, are characterized by an increase in body temperature, so temperature monitoring is a vital tool in the detection, diagnosis and prevention of the spread of disease. Nemaura is expecting to submit this adaptation of the device for regulatory clearance in 2022.

Market Opportunity

Obesity and diabetes are two of the major drivers of the current chronic disease epidemic. According to the International Diabetes Federation, there are more than 463 million people living with diabetes worldwide. In the U.S., about 28,000 people are diagnosed with diabetes every week, and more than 34 million suffer from diabetes. Another 88 million Americans have prediabetes. Other industrialized countries show similar numbers based on their populations. In the U.K., 4.8 million people have diabetes, with another diagnosed every two minutes. In Germany, 9.5 million have diabetes, with almost half estimated to be undiagnosed and so at greater risk.

On average, employers and insurers spend more than $9,000 annually on health care for an employee with diabetes, compared to $1,600 annually for a healthy employee. In the U.S. alone, more than $760 billion was spent on diabetes-related health care expenditures during 2019. Nemaura is positioned at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market, and the wearable health-tech sector for weight loss and wellness applications forecast to hit $60 billion by 2023.

Management Team

Dr. Faz Chowdhury has been CEO and chairman of the board of Nemaura Medical since 2013. He has more than 20 years of experience in the pharmaceutical and medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents and has authored textbook chapters on nano-biosciences for Wiley and Elsevier. He holds a master’s degree in microsystems and nanotechnology from Cranfield University, and a doctorate from the University of Oxford in nano-medicine and drug delivery.

Justin Mclarney is CFO at Nemaura. He most recently was the Senior Director, International Finance at Lands’ End Inc. He also worked for Office Depot as Senior Director of Finance for the largest business unit within the European group. Prior to that, he spent more than 10 years in practice, the majority of which was with Ernst & Young LLP.

Dr. Fred Schaebsdau is Vice President of Strategy & Strategic Alliances at Nemaura. He has more than 15 years of executive experience in the CGM, blood glucose monitoring and insulin delivery industries, including time with Abbott Diabetes Care, as General Manager of Dexcom Germany and at Roche Diabetes Care, where he was Senior Vice-President, Head of Global Strategy and Business Development. The firm he founded is the exclusive distributor in Europe, the Middle East and Africa of UniStrip®, the world’s first generic blood glucose test strip. He is licensed to practice medicine in the U.S. and Germany.

David Scott is Director of Commercial Development and Licensing at Nemaura. He is a trained chemist with over 35 years of experience in the pharmaceutical industry, including deal brokering, marketing, strategic planning, finance, business development and acquisitions. He has also provided licensing training for a number of multinational pharma companies and training organizations and is the author of best-selling report Scrip’s Practical Guide to Pharmaceutical Licensing.

Nemaura Medical Inc. (NASDAQ: NMRD), closed Tuesday's trading session at $4.85, off by 0.205761%, on 15,906 volume with 167 trades. The average volume for the last 3 months is 15,906 and the stock's 52-week low/high is $3.45/$17.40.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Asia Broadband (OTC: AABB) today announced its entry into a definitive purchase agreement to acquire a 100% interest in the Bonanza Gold Mine Project. According to the update, the company came to terms with Martin Augusto Vallejo Lujambio for the 19.25-hectare concession # 221977, Bonanza, located approximately 48 kms southeast from the city of Acaponeta and 3 kms from the town of El Carrizo, in Nayarit, Mexico. The property’s total purchase price was $6 million, split into $ 2 million cash and $ 4 million in restricted shares of Asia Broadband. The project is another prospective high-yield asset addition in AABB’s strategic expansion initiative to acquire gold production and increase physical gold holdings. To view the full press release, visit https://ibn.fm/oFlmY. In a broadcast aired in October, Tavi Costa, the portfolio manager of Crescat Capital, and Kevin Smith, the company’s chief investment officer, discussed how precious metals would do well in this current “stagflationary” environment. The portfolio manager asserted that the intrinsic value of these metals was remarkable, in relation to the monetary system in the United States. Smith explained that the company used precious metals as a primary hedge with gold particularly positioned against deep valuations and inflation. Both experts believe that a rally of precious metals is on the horizon, noting that silver is on the verge of a breakout, as demonstrated by its present position. Costa noted that silver was a valuable macro asset whose demand would probably be driven by the green revolution. All these factors create a perfect mix for increased performance by precious metals, including mining stocks such as those offered through Asia Broadband Inc. (OTC: AABB) and precious metals ETFs.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Tuesday's trading session at $0.17845, off by 5.1302%, on 30,516,345 volume with 2,180 trades. The average volume for the last 3 months is 30.516M and the stock's 52-week low/high is $0.003/$0.659.

Recent News

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

  • The pharmacy practice is undergoing an evolution that will see pharmacies play a more significant role in patient care
  • Expanded pharmacy technology has allowed pharmacists to better document patient care and results, and Avricore is playing a central role in making this possible
  • The company’s HealthTab(TM) platform supports multiple rapid, lab-accurate testing instruments, and acts as a network for exchanging and reporting data/results
  • Point-of-care testing has numerous benefits, including improved outcomes and quality of life for patients, limiting the spread of infectious diseases, faster treatment, shorter recovery times, and relieving overworked personnel in primary care centers

Health diagnostics technology innovator, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), is committed to moving pharmacy forward. Through its flagship HealthTab(TM) platform, the company turns pharmacies into community diagnostic centers, enabling pharmacists to take on more responsibilities in primary health services. With the community pharmacy practice experiencing an important transformation that will alter how the public thinks of community pharmacists’ role, Avricore is playing a central role in promoting this paradigm shift.

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Tuesday's trading session at $0.11339, off by 3.1682%, on 8,616 volume with 3 trades. The average volume for the last 3 months is 8,616 and the stock's 52-week low/high is $0.068/$0.48562.

Recent News

DigiMax Global Inc. (CSE: DIGI) (OTC: DBKSF)

The QualityStocks Daily Newsletter would like to spotlight DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF).

  • Global videogame revenue is expected to surge 20% to $179.7 billion in 2020
  • DigiMax is entering booming space through its partnership with BearClaw Esports
  • Agreement with BearClaw Esports brings a frictionless, nondisruptive adoption to a growing generation that desires and monetizes from technological advancement

As a result of the global pandemic, video games have emerged as a larger industry than sports and movies combined, according to MarketWatch (https://ccw.fm/krG3j). Savvy companies are looking to enter the booming space, and DigiMax Global (CSE: DIGI) (OTC: DBKSF) has done exactly that with its new partnership with BearClaw Esports, introducing the gaming industry to its cryptocurrency expertise (https://ccw.fm/5PMVJ).

DigiMax Global Inc. (CSE: DIGI) (OTCQB: DBKSF) is an artificial intelligence technology and services company producing and leveraging predictive indicators across various industries and verticals.

The company offers financial, business, and human capital AI predictive solutions to businesses, institutions, and consumers to improve decision-making.

The DigiMax core solutions are:

  1. CryptoHawk AI – CryptoHawk is a deep learning AI solution (SaaS) that monitors and analyzes live select cryptocurrencies and financial markets. The CryptoHawk AI solution is offered to retail clients as a monthly subscription. Generated data provides subscribers with price trend predictions for better investment strategies.
  2. Cryptocurrency Hedge Fund – A long/short cryptocurrency hedge fund for high net worth, institutional, and family office clients was launched on September 1, 2021. The company’s crypto hedge fund earns clients’ management and overall performance fees.
  3. Projected Personality Interpreter (PPI) – DigiMax solutions utilize AI to provide comparative insights for better hiring decisions, reduced employment attrition, improved workplace culture, and augmented human and financial predictive services by measuring and correlating personal attributes.
  4. Navee Predict – DigiMax data scientists provide companies with the unprecedented power of enhancing decision-making by analyzing, detecting changes and forecasting patterns.

The company’s team has extensive experience in finance, trading, machine learning (ML), neural language processing, AI, big data, and cryptocurrency technology. DigiMax leverages AI and its expert team to translate data into actionable predictive insights across the financial, business, and human dimensions, enhancing the decision-making capacity of organizations. DigiMax is an official IBM Watson partner with more than 30 years in data science and artificial intelligence.

Solutions

Business and Financial Capital Solutions

CryptoHawk AI

CryptoHawk.ai is a cryptocurrency price and trend prediction solution offered as a web application (https://cryptohawk.ai) and a mobile application by the end of 2021. The value for the user is to capture gains and take advantage of volatility while reducing risk and engaging in smarter and simpler trading.

The key features:

  • Trend Prediction Indicator (“TPI”)
    The TPI is a superior model that leverages the cryptocurrencies analyzed by the AI and other market-driven data and policies to produce actionable predictions in the form of:
    • Prediction cards
    • Cryptocurrency graphs with optional market indicators
    • Email/SMS alerts
  • Trend Watch
    Trend Watch is a one-week look ahead machine learning prediction for a select portfolio of mature cryptocurrencies. Trend Watch predicts a trend being UP or DOWN and provides a price target. Users have access to:
    • A list of select cryptocurrencies with predictive graphs

The system alerts investors through email and text messages when a price trend changes, allowing users to act confidently.

Cryptocurrency Hedge Fund

On September 1, 2021, DigiMax launched its Cryptocurrency Hedge Fund to offer high net worth, institutional, and family office clients a fully systematic long/short active investment into a basket of cryptocurrencies capitalizing on crypto volatility and powered by proprietary trading algorithms. The official launch is expected in the coming months.

The fund is led by 40-year hedge fund veteran Ian Hamilton and has an experienced investment and fund management team. This actively managed fund provides an excellent opportunity for larger investors to gain exposure to cryptocurrencies.

AI Business Prediction as a Service

The company offers predictive insights to businesses through automation and its innovative and proprietary AI and ML technology. Traditional models are expensive, because they are created and developed by data scientists dedicated to solving specific business questions that require costly customization and weeks, if not months, of development. With DigiMax, companies have access to solutions and services at a fraction of the price of traditional and experimental approaches. By combining AI with ML prediction technology, the company delivers insights on:

  • Sales forecasts
  • Optimal inventory levels
  • Supply chain management
  • Invoice payment projections
  • Targeted segmentation for marketing campaigns

Human Capital Solutions

AI-Powered Projected Personality Interpreter

The Projected Personality Interpreter (“PPI”) evaluates and improves customers’ workforce, brand and culture by revealing the personality traits and sentiment buried in human expression. The PPI empowers organizations with comparative insight for better hiring decisions, reducing employment attrition and improving workplace culture.

PPI provides a comprehensive and complete solution, offering:

  • Recruitment campaign management
  • Custom questionnaires, desirable traits recipes, and group likenesses
  • Detailed personality reports to compare and contrast peers
  • API for advanced integration with alternative systems of record

DigiMax leverages IBM Watson and a custom algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, providing hiring managers with a comprehensive report that improves decision making and takes the bias out of the process. The company’s solution is currently in use by 17 law enforcement agencies in North America and is used across the 10 global recruitment brands of Shepherd Search Group.

Market Overview

The AI industry has a five-year CAGR of 18.4%, with revenues projected to reach $37.9 billion by 2024. Some more optimistic forecasts have the market worth as much as $15 trillion by 2030. It’s estimated that 80% of all emerging technologies in 2021 have AI foundations. About 40% of all businesses use AI in their operations. According to Industry Ark, artificial intelligence use in the recruitment market was valued at $580 million in 2019.

Management Team

Chris Carl, CEO

Chris Carl has over 20 years of experience as a public-company CEO and has built several successful businesses across multiple categories. He has a proven ability to lead and has a track record of execution, revenue growth, and value creation.

Thierry Hubert, CTO

Thierry Hubert has 30 years of technology experience with Fortune 100 companies worldwide and is an early pioneer in applying artificial intelligence to solve big data and unstructured information challenges with IBM as a Director of R&D in emerging technology, knowledge management, and process innovation. He has received awards, recognitions, and grants that contributed to his ongoing collaboration with industry leaders.

David Bhumgara, CFO

David Bhumgara is a senior finance executive with over 25 years of leadership experience and proven expertise in finance, financial reporting, accounting, corporate finance, budgeting, financial modeling, and mergers & acquisitions.

Damon Stone, Trading Strategy Advisor

Damon Stone is an experienced stock and crypto trader who works very closely with the Cryptodivine.ai data science team as a subject matter expert. During 15 years at Merrill Lynch as a market maker and proprietary trader, he traded many different sectors, culminating in heading up a $250 million trading desk.

Ross Power, Senior Innovation Engineer
Ross Power is an experienced technical system architect with a demonstrated history of working on advanced technologies, including AI algorithms, IoT solutions, 3D printing, Innovation in BCI (Brain-Computer Interfacing), and RC flight and navigation systems.

DigiMax Global Inc. (DBKSF), closed Tuesday's trading session at $0.06, off by 3.0695%, on 19,950 volume with 13 trades. The average volume for the last 3 months is 19,950 and the stock's 52-week low/high is $0.05/$0.70.

Recent News

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), an emerging leader in innovative health and wellness beverages and products, has released its  unaudited financial results for the quarter ended Sept. 30, 2021; all numbers are in Canadian dollars. Among the highlights include a revenue growth figure of $1.1 million, which represents more than a 1,000% increase over the $94,000 reported in the same quarter last year. In addition, the company noted gross profit of $356,168 during Q3 2021, compared to a loss of $40,280 for Q3 2020. BevCanna closed the quarter with cash reserves of $655,563. Business highlights include a definitive agreement outlining the proposed acquisition of Embark Health Inc., a leader in solventless cannabis extraction and enhanced-delivery technology, and a second definitive agreement with the Tinley Beverage Company Inc. to comanufacture its award-winning cannabis-infused beverages for the Canadian market. BevCanna also saw product listing and purchase orders from British Columbia Liquor Distribution Branch (“BCLDB”), Alberta Gaming and Liquor Commission and Ontario Cannabis Store. “As we closed out the third quarter, we delivered impressive revenue growth of more than 1,000%, achieving $1.1 million in sales, compared to $94,000 in the year ago quarter,” said BevCanna chief financial officer John Campbell in the press release. “Our third-quarter results are further evidence of the company’s continued execution and the impact that our brands are having on the market. Our unique and diverse portfolio continues to expand, and with the impending close of our acquisition of Embark, will include an even wider range of adult-use and wellness channels and innovative product categories.” To view the full press release, visit https://ibn.fm/7fXqI. Marijuana products are legally available in Guam, Washington, DC, and 19 other states. In states where recreational marijuana is legal, THC-infused drinks such as Hi5, Kalo, Keef, Cann and Wunder are marketed alongside other drinks, including wine and beer. Today, we look at whether producers of alcoholic beverages should worry about competition from cannabis-infused drinks. Colleen McClellan of Datassential says that we are likely to see an increase in the use and interest in cannabis-infused drinks as more states relax their regulations on the herb. McClellan, who is the regional director of the leading food and beverage insights platform, noted that for repeat purchases, taste would be crucial for product adoption. As the nonalcoholic beverage and adult-use recreational cannabis markets continue to grow at this rapid pace with the entry of players such as BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), it is expected that the number of consumers switching to cannabis-infused drinks because of the benefits they offer may increase.

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

  • Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
  • Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
  • Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
  • Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
  • Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH).

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Tuesday's trading session at $0.1999, off by 0.14985%, on 163,994 volume with 62 trades. The average volume for the last 3 months is 163,994 and the stock's 52-week low/high is $0.172/$1.20.

Recent News

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

  • MCOA’s Q3 2021 revenue increased 731% year on year from $53,195 in Q3 2020 to $442,178 in Q3 2021
  • The company attributed this growth to its recent acquisition of cDistro, one of the fastest-growing distributors in North America
  • cDistro’s acquisition is part of a strategic shift as the company looks to expand into new areas within the cannabis industry
  • MCOA expects another record-breaking quarter in Q4 2021 as it anticipates reporting a full quarter of revenue from VBF Brands Inc., its newly acquired cultivation facility in Salinas, California

Marijuana Company of America (OTC: MCOA), a diversified holding company looking to grow its business and further establish itself in the legalized cannabis THC, hemp, and cannabidiol (“CBD”) industries, recently reported the highest quarterly revenue in its history (https://cnw.fm/CzXNG). 

Marijuana Company of America Inc. (OTC: MCOA) operates and invests in the cannabis sector directly. The company’s diverse operations include cDistro, one of the THC, hemp & CBD cannabis industries’ fastest growing distribution companies; hempsmart™, a premium CBD company; and VBF Brands Inc., a cannabis nursery cultivation facility in Salinas, California, that is a cultivator and distributor utilizing its own growing systems to produce desirable cannabis clones.

MCOA continues to grow its business while remaining fiscally conscious and further establishing itself in the legalized cannabis THC, hemp & CBD industries by offering unique exposure to the global cannabidiol sector. The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners.

Marijuana Company of America offers investors the opportunity to be at the forefront of innovation in the legal cannabis and industrial hemp industries.
During the summer of 2021, the U.S. witnessed the introduction of the most comprehensive cannabis reform ever proposed at the federal level, as well as ongoing state-level liberalization. The investments MCOA has made will position the company to drive the expected strongest revenue growth in the company’s history.

MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and partners with the best opportunities for rapid growth. It is MCOA’s attention to detail in producing premium products and adhering to the best business practices that distinguish it among the leaders of cannabis products in the global marketplace.

MCOA is building a portfolio of investments and joint ventures that represent the highest integrity and professionalism in the legal cannabis and industrial hemp markets. MCOA is a model for entrepreneurs and businesses that share its common goals and philosophies of not only creating value for investors but also creating an environment for businesses to improve the quality of life of customers through sustainable alternatives to many products currently on the market.

Partnerships and Investments

MCOA has partnered with and invested in a portfolio of companies operating in the cannabis sector. These include:

Cannabis Global Inc.

Cannabis Global Inc. (OTC: CBGL) is an emerging force in the cannabis marketplace with growing product and intellectual property portfolios. CBGL is marketing and producing Comply Bag™, an innovative solution for cannabis storage, transport, and tracking, and is also the developer and marketer of the Hemp You Can Feel™ brand.

Eco Innovation Group Inc.

Eco Innovation Group Inc. (OTC: ECOX) works with inventors and other professionals to nurture and catalyze the most innovative and impactful products and services and deliver those innovations to market. ECOX is dedicated to developing and commercializing successful products.

MCOA’s investment supports Eco Innovation’s cutting-edge extraction technology. ECOX’s extraction processes utilize a proprietary formulation to extract valuable bioactive compounds from cannabidiol (CBD) combined with plant-based materials to create a fluid and cost-effective output.

Together, both companies are positioned to identify and accelerate the development of new varieties of hemp-based products and distribute them worldwide.

Natural Plant Extract

MCOA owns a direct investment interest in Natural Plant Extract (NPE), which operates a licensed cannabis manufacturing and distribution business in Lynwood, California. NPE holds a Type 7 California manufacturing and distribution license, allowing for cannabis product distribution anywhere in the State of California.

Wholly Owned Subsidiaries

hempsmart™

hempsmart™ is a CBD company focused on creating and promoting the most effective, best tasting, and highest quality products on the market.

In 2021, hempsmart expanded into the global marketplace and announced a rebrand that featured a fresh take on its packaging and a social media campaign to engage customers via Instagram, Twitter, TikTok, and more, which has now generated a new loyal group of followers.

hempsmart premier products include its Smart Drops (CBD Drops), Neuro Smart (Patented Brain Pills), and Smart Cream (Pain Cream) brands. These organic, plant-based products help to manage anxiety, pain and insomnia, without the inclusion of THC.

cDistro

cDistro distributes CBD brands, along with smoke and vape shop-related products, to wholesalers, c-stores, specialty retailers, and consumers in North America.
cDistro was chosen as one of the first to distribute Marley One, the first global functional mushroom brand, in collaboration with the Bob Marley Family.
The initial product offering will include a range of functional mushroom tinctures, including species such as cordyceps, lion’s mane, chaga, reishi and turkey tail, that offer a range of unique health and wellness benefits, from immunity and gut health to cognitive function and sleep enhancement.

VBF Brands Inc.

MCOA recently completed the acquisition of VBF Brands Inc., a fully licensed marijuana cultivator and distributor based in Salinas, California. VBF utilizes its own growing systems to produce desirable cannabis clones that are designed to assist growers by reducing uncertainty and enhancing the likelihood of a successful cultivation harvest. Cannabis clones carry the exact same genetic potential as their mother plants and have similar cannabinoid and terpene profiles when grown properly.

This subsidiary will immediately work toward increasing production at its Salinas facility, which also offers exponential growth potential with other nearby properties that MCOA has an option to participate in as part of the acquisition.

Market Outlook

Ongoing changes in U.S. state government policies toward cannabis are expected to cause demand for legal marijuana to surge. In addition, the number of indications for which medical marijuana is prescribed continues to increase. These factors are expected to rapidly boost legal sales of cannabis products. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will increase opportunities for this market.

According to a Grand View Research report, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a CAGR of 26.7 percent from 2021 to 2028. That would put the market value at roughly $30 billion by 2025.

The report cites the growing number of countries that are legalizing cannabis as a driver for surging demand. It also points out the use of medical marijuana for various ailments is gaining momentum worldwide. Medical marijuana is prescribed for patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s and other neurological disorders. The demand for cannabis oil is also increasing rapidly, especially among countries with legalized medical marijuana.

Management Team

Jesus Quintero is the CEO and Chairman of MCOA. From January 2013 to September 2014, he was the Chief Financial Officer of Brazil Interactive Media Inc. Since 2011, he has served as a financial consultant to several multimillion-dollar businesses in South Florida. He has extensive experience in public company reporting and SEC/SOX compliance and held senior finance positions with Avnet Inc., Latin Node Inc., Globetel Communications Corp., and Telefonica of Spain. His prior experience also includes positions at Price Waterhouse and Deloitte & Touche. He holds a B.S. in Accounting from St. John’s University and is a certified public accountant.

Marijuana Company of America Inc. (MCOA), closed Tuesday's trading session at $0.00215, off by 6.5217%, on 52,376,987 volume with 219 trades. The average volume for the last 3 months is 52.377M and the stock's 52-week low/high is $0.0016/$0.0398.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading